Targeting immune cell types of tumor microenvironment to overcome resistance to PD-1/PD-L1 blockade in lung cancer
M Wang, L Zhu, X Yang, J Li, Y Liu… - Frontiers in …, 2023 - frontiersin.org
Lung cancer is the common malignant tumor with the highest mortality rate. Lung cancer
patients have achieved benefits from immunotherapy, including immune checkpoint …
patients have achieved benefits from immunotherapy, including immune checkpoint …
Tumor‐derived exosomal PD-L1: a new perspective in PD-1/PD-L1 therapy for lung cancer
Y Wu, H Fu, J Hao, Z Yang, X Qiao, Y Li… - Frontiers in …, 2024 - frontiersin.org
Exosomes play a crucial role in facilitating intercellular communication within organisms.
Emerging evidence indicates that a distinct variant of programmed cell death ligand-1 (PD …
Emerging evidence indicates that a distinct variant of programmed cell death ligand-1 (PD …
Exosomal microRNA levels associated with immune checkpoint inhibitor therapy in clear cell renal cell carcinoma
E Ivanova, D Asadullina, G Gilyazova, R Rakhimov… - Biomedicines, 2023 - mdpi.com
Immunotherapy with immune checkpoint inhibitors (ICIs) has shown high efficiency in clear
cell renal cell carcinoma (ccRCC) treatment. However, the response to therapy among …
cell renal cell carcinoma (ccRCC) treatment. However, the response to therapy among …
Taxifolin Inhibits the Growth of Non-Small-Cell Lung Cancer via Downregulating Genes Displaying Novel and Robust Associations with Immune Evasion Factors
X Lin, Y Dong, Y Gu, F Wei, J Peng, Y Su, Y Wang… - Cancers, 2023 - mdpi.com
Simple Summary Lung cancer (LC) is the leading cause of cancer deaths. While the current
immunotherapies are beneficial to patients, the effects are minimal and heterogeneous …
immunotherapies are beneficial to patients, the effects are minimal and heterogeneous …